Literature DB >> 15151940

Extravasation of systemic hemato-oncological therapies.

R A Ener1, S B Meglathery, M Styler.   

Abstract

Systemic intravenous chemotherapeutic agents can cause multiple emergency situations including acute and chronic local and systemic reactions. Amongst them, drug extravasation is one of the most devastating complications, as many drugs can cause varying degrees of local tissue injury when extravasated. Although it is difficult to give an accurate measurement, the incidence of extravasation of systemic infusional chemotherapeutic agents has been reported to occur in 0.1-6.5% of cases. Since most extravasations can be prevented with the systematic implementation of careful administration techniques, guidelines have been published for the administration of vesicant drugs. The proper maintenance of intravenous lines, application of local cooling or warming for certain extravasations, and the use of antidotes to prevent the local toxic action of the extravasated drugs are the basis of medical management. The specific antidotes for certain chemotherapeutic agents are also discussed in this article.

Mesh:

Substances:

Year:  2004        PMID: 15151940     DOI: 10.1093/annonc/mdh214

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  24 in total

Review 1.  [Antineoplastic drug-induced extravasation].

Authors:  Maike de Wit
Journal:  Med Klin (Munich)       Date:  2010-11

Review 2.  Overview, prevention and management of chemotherapy extravasation.

Authors:  Firas Y Kreidieh; Hiba A Moukadem; Nagi S El Saghir
Journal:  World J Clin Oncol       Date:  2016-02-10

3.  Management of extravasation of oxaliplatin by mimicking its biotransformation.

Authors:  F Bahadori; M Demiray
Journal:  Clin Transl Oncol       Date:  2018-04-27       Impact factor: 3.405

Review 4.  [Prevention, early diagnosis and treatment of chemoextravasation. Practical management in the uro-oncological practice].

Authors:  L Rinnab; M Ringhoffer; R Mayer-Steinacker; R E Hautmann; J Simon
Journal:  Urologe A       Date:  2009-11       Impact factor: 0.639

5.  A midline for oxaliplatin infusion: the myth of safety devices.

Authors:  Ben Masters; Tamas Hickish; Esther Uña Cidon
Journal:  BMJ Case Rep       Date:  2014-06-05

6.  Regimen of 5-Fluorouracil and Cisplatin Increases the Incidence of Extravasation in Patients Undergoing Chemotherapy.

Authors:  Hisashi Tagashira; Yasuhisa Izushi; Tomoki Ikuta; Yasumasa Koike; Yoshihisa Kitamura; Hiroshi Yamamoto
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

7.  Extravasation of oxaliplatin: an infrequent and irritant toxicity.

Authors:  C Pericay; A López; J R Soler; T Bonfill; E Dotor; E Saigí
Journal:  Clin Transl Oncol       Date:  2009-02       Impact factor: 3.405

8.  Optimal management of patients receiving cabazitaxel-based chemotherapy.

Authors:  Catherine Sperlich; Fred Saad
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

9.  Extravasational side effects of cytotoxic drugs: A preventable catastrophe.

Authors:  Jagdeep S Thakur; C G S Chauhan; Vijay K Diwana; Dayal C Chauhan; Anamika Thakur
Journal:  Indian J Plast Surg       Date:  2008-07

10.  Anthracycline extravasation injuries: management with dexrazoxane.

Authors:  Karin Jordan; Timo Behlendorf; Franziska Mueller; Hans-Joachim Schmoll
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.